The chapter delves into the potential benefits of using ultrasound for drug penetration, specifically in diseases like Alzheimer's, while emphasizing the speaker's strategy of targeting brain inflammation. The discussion touches on modifying inflammation in the blood to impact immune cell movement in the brain, eliminating the need to manipulate the blood-brain barrier.
Vention CEO Etienne Lacroix discusses how manufacturers are embracing AI and robotics when it comes to factory innovation. Howard Berman, Chairman and CEO of Coya Therapeutics breaks down a new approach to curing ALS. And we Drive to the Close with Lamar Villere, Portfolio Manager at Villere & Co.
Hosts: Carol Massar & Tim Stenovec Producer: Sara Livezey
See omnystudio.com/listener for privacy information.